• New antibiotics

    to save future generations


Using information buried in nature to make new antibiotics.

Institute of Metagenomics and Microbial Technologies (IMMT) is a biotechnology company committed to the discovery of new antibiotics to prevent and cure diseases caused by antibiotic-resistant bacteria. Antibiotic treatment failure of infectious diseases is a serious global public health problem. Already 70% of pathogenic bacteria are resistant to the currently used antibiotics which is associated with increased rates of morbidity and mortality. Each year at least 23,000 people die from an infection in the United States (source CDC) and the number of deaths is even larger in Europe (source WHO).

How to stop the increasing antibiotic treatment failure?

IMMT makes this possible thanks to PI Dr Ales Lapanje's extensive experience of more than 15 years of applied research in the field of molecular microbial ecology, supported by more than 40 independent academic and industrial projects. The team at IMMT works to provide novel solutions to treat infections.

Advisory board

Ales Lapanje, PhD

Dr Ales Lapanje
LinkedIn - Dr Ales Lapanje
Dr Ales Lapanje is a co-founder of Institute of Metagenomics and Microbial Technologies (IMMT) and a researcher at Jozef Stefan Institute (IJS), Slovenia, which is ranked among the top 10 research institutes in Europe. Dr Ales Lapanje received his PhD in molecular microbial ecology. He has 15 years of experience in environmental molecular microbiology, focusing on the functioning of microbial communities in various environments. He published 50 scientific articles, carried over 40 academic and industrial projects and holds 4 patents and 5 patent applications.

Dr Ales Lapanje has developed several technologies and commercial platforms which were commercialized by means of licensing as well as 5 spinoff companies. For his contributions in microbiology research he received awards such as FEMS-Federation of European Microbiologists award for research, World Federation of Scientists award, CCIS Innovation Award which is handed out by the Chamber of Commerce and Industry of Slovenia, and L'Oreal-UNESCO FWIS award for a woman scientist of the year where he was a supervisor.

Tomaz Rijavec, PhD

Dr Tomaz Rijavec
LinkedIn - Dr Tomaz Rijavec
Dr Tomaz Rijavec is a co-founder of IMMT and a researcher at the Department of Environmental Sciences at Jozef Stefan Institute. He holds a PhD in molecular biology. He has more than 10 years of research experience in the field of molecular biology and biochemistry. His work has been focused on studying the functioning of microbial communities, host-microbe interactions and characteristics of different micro-environments.

Dr Tomaz Rijavec has been involved in several national and international applicative projects, aiming to translate basic science into applicative solutions. He has supervised the setting up of several analytics pipelines and laboratories for molecular biology. He is an expert at method development and validation.

Jan Zrimec, PhD

LinkedIn - Dr Jan Zrimec
Dr Jan Zrimec is a postdoctoral researcher at the Faculty of Health Sciences, University of Primorska, Slovenia. He has a PhD in bioinformatics and he was recently awarded the National ARRS postdoctoral research fellowship.

Dr Jan Zrimec has over 6 years of experience in computational biology and bioinformatics of DNA signatures. The aim of his work is to develop bioinformatic algorithms based on computation and analysis of DNA structure and horizontal gene transfer to:
- analyse and reduce the emergence of antibiotic resistance in bacterial communities,
- improve the efficiency and accuracy of discovery of new bioactive compounds useful in industrial and medical applications.


The window of opportunity is now

Driven by the belief that our team at the Institute of Metagenomics and Microbial Technologies (IMMT) can make a great contribution to the end of the global problem of antibiotic treatment failure, we put all our knowledge, effort and time into making a significant solution. Our solution is based on the strong fundamental knowledge of environmental molecular microbiology which was gained over more than a decade of scientific and applicative research.

The IMMT's competition builds their antibiotic pipeline mainly by exploiting antibiotics from bacteria that can be cultured in the laboratory, which is approximately 0.01% of all bacterial genera. But IMMT uses a functional metagenomic* approach and can exploit all bacteria, thus it is 10,000 times more efficient at finding new antibiotic compounds than the competition.
*Functional metagenomics - collecting and analyzing microbes' genetic material recovered directly from the environment.

Current antibiotic development is not able to follow the market needs due to the fast occurrence of antibiotic resistant microbes. At IMMT we understand that this is a great business opportunity. Therefore, the most important feature of our solution is to industrialize the functional metagenomic pipeline. IMMT uses not only proven techniques but also innovates the business model.

At the moment we are looking for strategic partners and investors to help us realize our vision of creating a new platform for the discovery of antibiotics that will benefit present and future generations. Please contact us by E: immt@immt.eu or T: +386 (0)41 925 729.


25 July 2016

Cooperation with dr Gunter Festel discontinued

IMMT and dr. Gunter Festel have agreed not to continue with further cooperation. During the negotiation phase we were not able to reach a compromise for a formal agreement. We want to thank dr. Festel for his contribution and wish him much success with his ongoing business projects and his further career challenges.

26 May 2016

Gunter Festel joins the Slovenian Biotechnology Company IMMT (Press Release)

Gunter Festel joins the Institute of Metagenomics and Microbial Technologies (IMMT) as shareholder and non-executive director bringing in his network within the biotechnology industry and financing community

The Institute of Metagenomics and Microbial Technologies (IMMT) is a biotechnology company established in 2014 by Ales Lapanje in Ljubljana, the Slovenian capital. Researching the field of metagenomics, IMMT strives to identify new natural compounds produced by microbes. IMMT has a proven track record in the scientific community with collaborations with renowned academic institutions and technology institutes around the world.

The engagement of Gunter Festel as shareholder and non-executive director strengthens the business development activities and supports future financing rounds of IMMT. Gunter Festel is a successful entrepreneur who has co-founded, as a Founding Angel, more than 10 biotechnology companies in Germany and Switzerland. For example, he was a co-founder and CEO of Butalco, a company developing a technology platform for the production of biofuels and biochemicals which was sold to the French company Lesaffre in 2014. This technology enables biofuel producers to use waste material instead of food to solve the ''food vs. fuel'' dilemma.

About IMMT

IMMT Ltd. is a biotechnology company working in the field of environmental molecular microbiology. Its founders have gained wide experience in analysing the functioning of microbial communities in the last 15 years. The research work was carried out in various environments such as soil, biofilms in marine and alpine regions, hotsprings, glaciers, animal and human microbiome. By working on over 40 research and industrial projects, IMMT founders have developed proprietary technologies for the extraction and processing of information of DNA from bacteria present in native environments. IMMT is aiming to commercialise its technology platform which enables to obtain information coded in DNA from unculturable bacteria. Our The solutions are suitable for the use in industrial and medical applications as well as to develop customised solutions based on this approach.

Contact: Blaz Petric, T: +386 41 966 665, E: info@immt.eu

Contact us


Institute of Metagenomics and Microbial Technologies Ltd. (IMMT)
Clevelandska 19
SI - 1000 Ljubljana


+386 (0)68 604 979